MTOR and cancer: The second generation ATP-competitive kinase-targeting mTOR inhibitors (OSI-027 [8], INK-128 [9], and CC-223 [10]) inhibit both mTORC1 and mTORC2 complexes and are currently being tested in clinical studies for cancer treatment.